FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3038916963> ?p ?o ?g. }

• W3038916963 endingPage "5264" @default.
• W3038916963 startingPage "5255" @default.
• W3038916963 abstract "Synovial sarcoma (SS) is a highly aggressive soft-tissue sarcoma (STS) with poor prognosis. Tyrosine kinase inhibitor (TKI) has shown a promising impact on advanced STS patients. This study aimed to evaluate the efficacy and safety of apatinib, an oral multi-TKI, which especially inhibited vascular endothelial growth factor receptor, as second-line therapy for patients with advanced SS.This retrospective analysis included 21 advanced SS patients, who had a poor response to anthracycline-based chemotherapy alone or combined with ifosfamide at least one cycle. All the patients received an apatinib containing regimen between May 2016 and October 2019 in our institution. Apatinib 500-750 mg (250 mg for patients younger than 10) was given daily. Tumor responses were assessed by response evaluation criteria in solid tumors. Survival analysis was performed by the Kaplan-Meier test, and a safety profile was recorded.The median follow-up was 15.2 months (95% CI, 12.2-NE). Nine (42.9%) patients had partial response (PR), and eight (38.1%) had stable disease. The median progression-free survival (PFS) was 13.1 months (95% CI, 6.7-NE). The 6- and 12-month PFS rates were 76.2% (95% CI, 60.0-96.8) and 55.4% (95% CI, 37.3-82.3), respectively. Additionally, the median overall survival (OS) was 15.5 months (95% CI, 10.7-NE). The 6- and 12-month OS rates were 81.0% (95% CI, 65.8, 99.6) and 64.9% (95% CI, 46.9-90.0), respectively. Moreover, the objective response rate was 42.9% (9/21) for advanced SS patients. The disease control rate was 81.0% (17/21). For the nine patients with the best response of PR, the median duration of response was 7.7 months.Apatinib was proved to be a potential second-line treatment option for advanced SS patients with chemo-resistance. Apatinib showed promising efficacy and acceptable safety profile in advanced SS, with considerable OS and particularly PFS. Indeed, further multicenter studies with a longer follow-up time are needed to fully determine the clinical application of apatinib in advanced SS." @default.
• W3038916963 created "2020-07-10" @default.
• W3038916963 creator A5000963442 @default.
• W3038916963 creator A5008037931 @default.
• W3038916963 creator A5012416384 @default.
• W3038916963 creator A5026197623 @default.
• W3038916963 creator A5049927484 @default.
• W3038916963 creator A5054109175 @default.
• W3038916963 creator A5061311697 @default.
• W3038916963 creator A5067786874 @default.
• W3038916963 creator A5072409091 @default.
• W3038916963 date "2020-07-01" @default.
• W3038916963 modified "2023-10-16" @default.
• W3038916963 title "<p>The Efficacy and Safety of Apatinib in Advanced Synovial Sarcoma: A Case Series of Twenty-One Patients in One Single Institution</p>" @default.
• W3038916963 cites W1965318510 @default.
• W3038916963 cites W1995357936 @default.
• W3038916963 cites W1999662775 @default.
• W3038916963 cites W2013696012 @default.
• W3038916963 cites W2019607817 @default.
• W3038916963 cites W2069926948 @default.
• W3038916963 cites W2088018126 @default.
• W3038916963 cites W2101776780 @default.
• W3038916963 cites W2105968397 @default.
• W3038916963 cites W2107230638 @default.
• W3038916963 cites W2117431699 @default.
• W3038916963 cites W2144530818 @default.
• W3038916963 cites W2145092426 @default.
• W3038916963 cites W2160028990 @default.
• W3038916963 cites W2276228008 @default.
• W3038916963 cites W2284990809 @default.
• W3038916963 cites W2294806546 @default.
• W3038916963 cites W2318344307 @default.
• W3038916963 cites W2537836937 @default.
• W3038916963 cites W2592028643 @default.
• W3038916963 cites W2616934252 @default.
• W3038916963 cites W2653632515 @default.
• W3038916963 cites W2735571771 @default.
• W3038916963 cites W2737533386 @default.
• W3038916963 cites W2773879876 @default.
• W3038916963 cites W2775931026 @default.
• W3038916963 cites W2799341684 @default.
• W3038916963 cites W2808647193 @default.
• W3038916963 cites W2808938770 @default.
• W3038916963 cites W2897295977 @default.
• W3038916963 cites W2898648857 @default.
• W3038916963 cites W2922332121 @default.
• W3038916963 cites W2996007848 @default.
• W3038916963 cites W4248877280 @default.
• W3038916963 cites W4285097283 @default.
• W3038916963 doi "https://doi.org/10.2147/cmar.s254296" @default.
• W3038916963 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7335867" @default.
• W3038916963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32669874" @default.
• W3038916963 hasPublicationYear "2020" @default.
• W3038916963 type Work @default.
• W3038916963 sameAs 3038916963 @default.
• W3038916963 citedByCount "9" @default.
• W3038916963 countsByYear W30389169632020 @default.
• W3038916963 countsByYear W30389169632021 @default.
• W3038916963 countsByYear W30389169632022 @default.
• W3038916963 crossrefType "journal-article" @default.
• W3038916963 hasAuthorship W3038916963A5000963442 @default.
• W3038916963 hasAuthorship W3038916963A5008037931 @default.
• W3038916963 hasAuthorship W3038916963A5012416384 @default.
• W3038916963 hasAuthorship W3038916963A5026197623 @default.
• W3038916963 hasAuthorship W3038916963A5049927484 @default.
• W3038916963 hasAuthorship W3038916963A5054109175 @default.
• W3038916963 hasAuthorship W3038916963A5061311697 @default.
• W3038916963 hasAuthorship W3038916963A5067786874 @default.
• W3038916963 hasAuthorship W3038916963A5072409091 @default.
• W3038916963 hasBestOaLocation W30389169631 @default.
• W3038916963 hasConcept C121608353 @default.
• W3038916963 hasConcept C126322002 @default.
• W3038916963 hasConcept C141071460 @default.
• W3038916963 hasConcept C142724271 @default.
• W3038916963 hasConcept C143998085 @default.
• W3038916963 hasConcept C197934379 @default.
• W3038916963 hasConcept C2776694085 @default.
• W3038916963 hasConcept C2776802502 @default.
• W3038916963 hasConcept C2776910622 @default.
• W3038916963 hasConcept C2778256501 @default.
• W3038916963 hasConcept C2778629024 @default.
• W3038916963 hasConcept C2780668389 @default.
• W3038916963 hasConcept C2780739268 @default.
• W3038916963 hasConcept C2781413609 @default.
• W3038916963 hasConcept C530470458 @default.
• W3038916963 hasConcept C71924100 @default.
• W3038916963 hasConcept C90924648 @default.
• W3038916963 hasConceptScore W3038916963C121608353 @default.
• W3038916963 hasConceptScore W3038916963C126322002 @default.
• W3038916963 hasConceptScore W3038916963C141071460 @default.
• W3038916963 hasConceptScore W3038916963C142724271 @default.
• W3038916963 hasConceptScore W3038916963C143998085 @default.
• W3038916963 hasConceptScore W3038916963C197934379 @default.
• W3038916963 hasConceptScore W3038916963C2776694085 @default.
• W3038916963 hasConceptScore W3038916963C2776802502 @default.
• W3038916963 hasConceptScore W3038916963C2776910622 @default.
• W3038916963 hasConceptScore W3038916963C2778256501 @default.
• W3038916963 hasConceptScore W3038916963C2778629024 @default.

• next